SCHEMBL209305

SCHEMBL209305

CCOC(=O)Cc1ccc(-c2csc(Nc3ccc(OCCCCc4ccccc4)c(F)c3)n2)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HDAC1 Q13547 1/20 0.39
DHODH Q02127 3/20 0.39
PTGES O14684 1/20 0.38
CFTR P13569 1/20 0.37
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
LMNA P02545 2/20 0.37
PARP1 P09874 1/20 0.37
TP53 P04637 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207141 0.91 HDAC8 (0.44) HDAC8CA12CA1CA2CA9
SCHEMBL207932 0.90 DHODH (0.40) HDAC8CA12CA1CA2CA9
SCHEMBL205834 0.81 MEN1 (0.39) HDAC8MAPTSMN1; SMN2HDAC1DHODH
SCHEMBL206271 0.81 HDAC8 (0.43) HDAC8CA12CA1CA2CA9
SCHEMBL207791 0.80 HDAC8 (0.44) HDAC8CA12CA1CA2CA9
SCHEMBL206860 0.80 HDAC8 (0.52) HDAC8CA12CA1CA2CA9
SCHEMBL207828 0.79 ALDH1A1 (0.45) HDAC8MAPTSMN1; SMN2HDAC1DHODH
SCHEMBL207889 0.78 MAPT (0.37) MAPTSMN1; SMN2DHODHCFTRGAA
SCHEMBL209137 0.77 S1PR1 (0.39) HDAC8MAPTSMN1; SMN2HDAC1GAA
SCHEMBL2705660 0.77 DHODH (0.39) HDAC8MAPTSMN1; SMN2HDAC1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 HDAC8 961/4885CA12 3857/4885CA1 2690/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 HDAC8 961/4885CA12 3857/4885CA1 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.